ProCE Banner Activity

CE / CME

The Evolving Role of Cytokine-Based Therapy in Patients With Melanoma Progression and/or Drug Resistance

Learn how experts leverage cytokine therapy for optimal treatment of patients with advanced melanoma in this on-demand webcast capturing a live CCO webinar.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: April 08, 2021

Expiration: April 07, 2022

No longer available for credit.

Share

Faculty

Ahmad Tarhini

Ahmad Tarhini, MD, PhD

Assistant Professor of Medicine
Department of Medicine/Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

George Ebanks

George Ebanks, RN, BSN, OCN

Cutaneous Medical Oncology Nurse
Cutaneous Oncology Program
Moffitt Cancer Center
Tampa, Florida

Jennifer Swank

Jennifer Swank, PharmD, BCOP

Clinical Pharmacy Specialist, Medical Oncology
Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Clinigen Inc

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan effective and safe therapy for melanoma in the setting of resistance and/or disease progression following targeted therapies.
  • Manage treatment-related adverse events in patients with progressive metastatic melanoma
  • Identify patients with pretreated, progressive melanoma suitable for enrollment on ongoing clinical studies investigating novel cytokine-based combination strategies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Ahmad Tarhini, MD, PhD

Assistant Professor of Medicine
Department of Medicine/Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Ahmad Tarhini, MD, PhD, has disclosed that he has received funds for research support from Clinigen, Genentech/Roche, and OncoSec and consulting fees from Bristol-Myers Squibb, Clinigen, Eisai, Genentech/Roche, Merck, Novartis, and Partner Therapeutics.

Faculty Disclosure

Primary Author

George Ebanks, RN, BSN, OCN

Cutaneous Medical Oncology Nurse
Cutaneous Oncology Program
Moffitt Cancer Center
Tampa, Florida

George Ebanks, RN, BSN, OCN, has no relevant conflicts of interest to report.

Jennifer Swank, PharmD, BCOP

Clinical Pharmacy Specialist, Medical Oncology
Moffitt Cancer Center
Tampa, Florida

Jennifer Swank, PharmD, BCOP, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-074-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 08, 2021, through April 07, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.